Determining When to Utilize Combination Approaches in EGFR+ NSCLC

Samuel Rosner, MD, and Laura Alder, MD, examine considerations for choosing between EGFR TKI monotherapy and emerging combination strategies in the frontline setting for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Alder discusses how recent data for regimens such as osimertinib (Tagrisso) plus chemotherapy and amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) have expanded therapeutic options for patients with EGFR-mutated NSCLC. Rosner highlights scenarios in which monotherapy may still be appropriate, emphasizing the importance of balancing efficacy, toxicity, and patient-specific factors.